1.04
+0.01(+0.97%)
Currency In USD
Address
322 11th Avenue SW
Calgary, AB T2R 0C5
Canada
Phone
14036707380
Sector
Healthcare
Industry
Biotechnology
Employees
28
First IPO Date
October 05, 2001
| Name | Title | Pay | Year Born |
| Mr. Jared Kelly J.D., L.L.M. | Chief Executive Officer & Director | 0 | N/A |
| Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant | 18,486 | N/A |
| Ms. Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development | 348,026 | N/A |
| Ms. Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations | 384,535 | N/A |
| Mr. Kirk J. Look C.A., CPA | Chief Financial Officer | 480,439 | N/A |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer | 572,430 | N/A |
| Mr. Andrew P. Aromando | Chief Business Officer | 0 | 1969 |
| Jon Patton | Director of Investor Relations & Communication | 0 | N/A |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.